

# Managing Heart Failure in Primary Care



U.S. Department of Veterans Affairs

Veterans Health Administration PBM Academic Detailing Services

# Key takeaways

Identify and treat risk factors for heart failure such as hypertension, diabetes, and atrial fibrillation to prevent or delay the development of heart failure.

To improve mortality and morbidity in patients with HFrEF, initiate and titrate angiotensin receptor blockers (ARNI/ACEI/ARB), beta blockers, SGLT-2 inhibitors, and mineralocorticoid receptor antagonists to target doses, or maximally tolerated dose.

In patients unable to tolerate dose titration due to hypotensive symptoms, utilize lowest tolerated doses of GDMT to improve morbidity and mortality.

For patients with HFpEF, manage contributing comorbidities, use diuretics to control fluids, initiate an SGLT-2 inhibitor, and consider an ARNI or MRA in selected patients.

Avoid using non-dihydropyridine calcium channel blockers, nifedipine, cilostazol, NSAIDs, and thiazolidinediones (e.g., rosiglitazone, pioglitazone) in HFrEF patients to prevent exacerbation of HF symptoms and hospitalizations.

Engage patients in appropriate care coordination, including RPM-HT, referring to cardiology specialists and post-hospitalization follow-up.



1

2

3

4

5

6

U.S. Department of Veterans Affairs

Veterans Health Administration PBM Academic Detailing Services

These materials were developed by:

**VA PBM Academic Detailing Services** Your Partner in Enhancing Veteran Health Outcomes

### **Table of contents**

Heart failure epidemiology	2
Preventing heart failure	3
Identifying heart failure in those at risk	4
Components of heart failure management	5
Medications for heart failure with reduced ejection fraction (HFrEF)	6
Angiotensin system blockers	7
Beta blockers (BB)	10
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors	11
Mineralocorticoid receptor antagonists (MRA)	12
Hydralazine and isosorbide dinitrate	13
Other medications used in selected patients with HFrEF	14
Medications for heart failure with preserved ejection fraction (HFpEF)	15
Assessing heart failure symptoms and fluid management	16
Treatment of heart failure in patients with chronic kidney disease (CKD)	19
Medications to avoid or use with caution in heart failure	21
Medication treatment algorithm	23
Care coordination	24
Summary	25
References	26

# Heart failure epidemiology

Heart failure (HF) affects about 6 million people in the U.S.—a number expected to increase to more than 8 million by 2030.<sup>1</sup> HF is one of the most common reasons for hospitalizations and is the most expensive Medicare diagnosis.<sup>2</sup> It is also one of the leading causes of hospital admissions in VA.




Figure 1. Heart failure is a leading cause of hospitalization in veterans

Data obtained from the Ambulatory Care Sensitive Conditions (ACSC) Dashboard on the Veterans Health Administration Support Service Center (VCSS) Capital Assets Databases from December 2020 to November 2021. Hospitalizations due to ACSC such as hypertension, heart failure, and pneumonia can be largely avoided and prevented if ambulatory care is provided in a timely and effective manner. COPD = chronic obstructive pulmonary disease; UTI = urinary tract infections.

# Although survival after HF diagnosis has improved over the past several decades, around 42% of patients will die within five years of diagnosis.<sup>1</sup>

Morbidity and mortality associated with HF are high, but using appropriate evidencebased treatments allows Veterans to live longer and have a better quality of life.<sup>2</sup> This module reviews evidence-based practices for the evaluation and management of HF in primary care settings.

# **Preventing heart failure**

Traditional heart failure risk factors:<sup>2-4</sup>

- Coronary heart disease
- Diabetes
- Hypertension
- Obesity
- Smoking
- Valvular disease
- Substance abuse (e.g., alcohol, cannabis, cocaine)


Obesity and insulin resistance are important factors for the development of HF.<sup>2</sup> For every 1% rise in hemoglobin (Hgb) A1c above 7%, the risk for developing heart failure increases by 12%.<sup>12</sup>


Many factors are associated with an increased risk of developing HF. Identification and treatment of these conditions has been proven to reduce the development of HF.<sup>2</sup>

For example:


- Optimized blood pressure leads to decreased risk of cardiovascular death and incidence of HF.<sup>5,6</sup>
- The treatment of hyperlipidemia with statins reduces risk in at-risk patients.<sup>7,8</sup>
- Use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduces the incidence of HF in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD).<sup>9-11</sup>

Identify and treat risk factors to prevent or delay the development of HF.





# Figure 3. Poor HbA1c control associated with an increased risk of HF<sup>12</sup>



# Identifying heart failure in those at risk

**BNP and NT-proBNP** 

may be falsely low in

patients with obesity.

A high value is predictive, but a low value in an obese patient does not exclude HF.

Early detection of elevated biomarkers, B-type natriuretic peptide (BNP), or N-terminal pro-B-type natriuretic peptide (NT-proBNP) can assist in identifying patients at risk for developing left ventricular dysfunction and subsequent HF.

Figure 4. Using biomarkers to reduce HF risk<sup>13-16</sup>

**Assess biomarkers** in patients with After risk factors **Optimize treatment HF risk factors** are treated and if of risk factors hypertension control blood pressure elevated levels hypercholesterolemia • manage diabetes  $BNP \ge 50 \text{ pg/mL OR}$ • obesity (BMI >  $30 \text{ kg/m}^2$ ) reduce ASCVD risk NT-proBNP  $\geq$  125 pg/mL\*) vascular disease • support healthy weight diabetes Consider echocardiogram reduction arrhythmia and referral to a valvular disease cardiovascular specialist

\*Anemia may lead to elevated levels. BMI = body mass index; ASCVD = atherosclerotic cardiovascular disease

Optimize management of risk factors and pharmacologic, and non-pharmacologic therapies in patients at risk for HF.<sup>2</sup>

### Diagnosing and classifying heart failure

Diagnosis of heart failure requires structural or functional changes to the heart and clinical signs and symptoms (e.g., shortness of breath, fatigue, exercise intolerance, coughing, **volume overload** such as ascites, lower extremity swelling, and weight gain).

Acronym	Classification	<b>Ejection fraction</b>	Description
HFrEF	HF with reduced EF	≤ 40%	Previously referred to as "systolic HF." Guideline- directed medical therapy (GDMT) should be initiated and optimized as tolerated.
HFpEF	HF with preserved EF	≥ 50%*	Previously referred to as "diastolic HF." Diagnosis of exclusion. Evidence-based therapies are limited.
HFmrEF	HF with mildly reduced EF	41-49%*	Trend toward treating like HFrEF. No major clinical trials in this population; it is unclear whether characteristics and outcomes are more like HFpEF.
HFimpEF	HF with improved EF	Previously ≤ 40% and a subsequent measurement > 40%	Continue GDMT for HFrEF, if tolerating. Further data needed to determine best management strategy.

Table 1. Classifications for heart failure<sup>16</sup>

\*With evidence of spontaneous or provokable increased left ventricular filling pressures (e.g., elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement); EF = ejection fraction

# Components of heart failure management


### Table 2. Principles of HF management<sup>16-20</sup>

	<ul> <li>Optimize medications</li> <li>Initiate GDMT and titrate where appropriate.</li> <li>Avoid medications that may worsen HF (e.g., NSAIDs). See page 14 for additional medications.</li> </ul>
	<ul> <li>Assess volume status</li> <li>Evaluate symptoms of fluid overload.</li> <li>Initiate and adjust diuretic to lowest effective dose.</li> <li>Consider fluid restriction in selected patients.</li> </ul>
	<ul> <li>Review dietary patterns</li> <li>Recommend sodium reduction. Reduce intake to &lt; 2,300 mg/day for general CV health promotion (optimal goal in HF unknown).</li> <li>Refer to nutrition.</li> </ul>
	<ul> <li>Engage patient in self-care*</li> <li>Take and record daily weight.</li> <li>Monitor and record blood pressure and heart rate.</li> <li>Self-monitor HF symptoms.</li> </ul>
Х́Х	<ul> <li>Encourage physical activity</li> <li>Increase regular physical activity in patients who are able to participate.</li> <li>Consider referral to cardiac rehabilitation for symptomatic (NYHA Class II-III) HF patients with EF ≤ 35% despite GDMT.</li> </ul>
	<ul> <li>Utilize care coordination</li> <li>Utilize Remote Patient Monitoring–Home Telehealth (RPM-HT).</li> <li>Refer to cardiology when appropriate.</li> <li>Refer to other team members (e.g., PACT pharmacist or nurse, physical therapist, social worker, psychologist, dietician, whole health team).</li> <li>Follow-up with Veteran, generally within seven days of hospital discharge.</li> <li>Assess for sleep-disordered breathing and treat as appropriate.</li> <li>Discuss/refer to palliative care.</li> </ul>

\*Confirm that the patient has a reliable scale and blood pressure cuff. NSAID = nonsteroidal anti-inflammatory drug; GDMT = guideline directed medical therapy; PACT = patient aligned care team; CV = cardiovascular; NYHA = New York Heart Association

# **Medications for HFrEF**

GDMT for patients with HFrEF focuses on four main medication classes to reduce mortality and morbidity. Veterans should be prescribed a medication from each pillar and have doses titrated to target doses to optimize benefit.<sup>17</sup> Achievement of optimal doses of initial medication(s) not required prior to adding the next medication and no specific order for initiation has been established or recommended.



### Figure 5. Foundational GDMT for patients with HFrEF<sup>17</sup>

\*Guideline-directed beta-blockers include bisoprolol, carvedilol, or metoprolol succinate.

The following recommendations are for patients with HF with *reduced* EF. For medication review for patients with HF with *preserved* EF see page 15.

### Tips for monitoring medications for heart failure:


- Laboratory monitoring
  - Electrolytes (especially serum potassium)
  - Renal function
- Blood pressure
  - Many of the medications used to treat HFrEF can have an impact on BP. Start low and monitor BP when initiating these medications in patients with already low BP. Ensure timely follow-up in the clinic or utilizing telehealth.
  - Do not stop GDMT in patients with low BP unless symptomatic. See the Quick Reference Guide (QRG) for guidance on managing symptomatic low BP.
  - Amend prescription indication to 'for the heart' to prevent discontinuation due to incorrect indication (i.e., blood pressure).
- Heart rate

## Angiotensin system blockers

Angiotensin system blockers include angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and angiotensin receptor/neprilysin inhibitors (ARNI).

Sacubitril/valsartan is preferred over an ACEI or ARB in patients with NYHA II-III symptoms in combination with other GDMT.<sup>17,21</sup>

# Figure 6. Sacubitril/valsartan reduced composite outcome of CV death and HF hospitalization more than enalapril



In the PARADIGM-HF trial, the composite outcome of CV death and HF hospitalization was lower in patients on sacubitril/valsartan than those on standard therapy (HR 0.8; 95% CI 0.73–0.87; p <0.001).

Symptomatic hypotension was significantly more frequent with sacubitril/ valsartan (14%) than enalapril (9.2%; p<0.001). No statistical difference in incidence of angioedema between the two groups, though patients with any history of angioedema were excluded.<sup>21</sup>

Sacubitril/valsartan can be safely initiated and titrated in primary care.

Consider switching patients on ACEI or ARB to an ARNI.

### Table 3. Prescribing sacubitril/valsartan

1. Select starting	dose		
Is patient switching from an ACEI/ARB?	Yes*	Ensure STRICT washout period for ACEI: Start sacubitril/valsartan 36 hours after the last dose of ACEI. Washout period is not required for ARBs. ACEI, ARB, and ARNI should not be taken concurrently.	
		LOW dose ACEI/ARB (daily dose $\leq$ 10 mg enalapril, $\leq$ 160 mg valsartan, $\leq$ 10 mg lisinopril, $\leq$ 100 mg losartan or equivalent)	24/26 mg twice daily
		High dose ACEI/ARB (daily dose > enalapril 10 mg, valsartan 160 mg, lisinopril 10 mg, or equivalent)	49/51 mg twice daily
	No	No current ACEI or ARB therapy	24/26 mg twice daily
Metabolic dose adjustmentsRenalHepatic	eGFR <30 mL/min/1.73m <sup>2</sup>	24/26 mg twice daily	
	llonatio	Child-Pugh Class B	24/26 mg twice daily
	перацс	Child-Pugh Class C	Not recommended

### 2. Monitor within 2-4 weeks of initiation and each dose titration:

- blood pressure
- electrolytes
- renal function

### 3. Double dose every 2-4 weeks as tolerated to target 97/103 mg twice daily

\*Recommendations for stable and acceptable blood pressure. For patients who have symptomatic hypotension, start with a lower dose of ARNI.

### Reminders for safe use of sacubitril/valsartan:

- Do not use in patients with any history of angioedema, not only to an ACEI or ARB.<sup>17</sup>
- Do not use with potassium > 5.5 mEq/L.
- Do not use within 36 hours of an ACEI or concomitantly with an ARB.<sup>17</sup>
- Caution in patients with NYHA class IV, as it is not as well tolerated and failed to show benefit in the LIFE trial.<sup>22</sup>

#### Clinical pearls: managing common situations with ACEI, ARB, or ARNI therapy My patient has mild • Evaluate for symptoms of hyperkalemia such as muscle hyperkalemia (< 6 mEg/dL) after weakness, paresthesias, muscular fasciculations, or cardiac starting treatment arrhythmias and take appropriate action if present. • Review other medications that may increase potassium. K+ • Reduce or discontinue potassium supplements. • Counsel on low K+ diet, consider referral for nutrition education. • Reduce dose of sacubitril/valsartan to highest tolerated dose. • Consider K+ binder, if appropriate. • Repeat serum potassium measurement as clinically indicated. Consider reducing or temporarily holding diuretic dose\*, My patient has symptomatic hypotension if appropriate. • Consider reducing or discontinuing other blood pressure medications not indicated for heart failure. If unable to decrease diuretic or antihypertensive medications, consider reducing the dose of sacubitril/valsartan. • > 30% decrease in eGFR or development of hyperkalemia. When is worsening renal function If hypovolemic, reduce diuretic dose.\* of concern? • If euvolemic, consider reducing sacubitril/valsartan dose or reducing/holding MRA. Rule out additional causes. \*Reducing diuretic dose can increase K+ levels.

- If an ARNI is not tolerated or appropriate, an ACEI or ARB may reduce mortality and HF hospitalization by 26% compared to placebo.<sup>17,23-25</sup>
- Titrating an ARNI, ACEI, or ARB to target dose decreases HF-related hospitalization and composite of all-cause death.<sup>24,26</sup>



Did you know? An ARB may be considered in patients with a history of ACEI-induced angioedema.

Initial considerations	<ul> <li>Consider the risk vs. benefit of ARB therapy in patient with a history of angioedema on an individual basis (e.g., severity of angioedema, patient's ability to recognize recurrence).</li> <li>ARNIs should not be considered in patients with a history of ACEI-induced angioedema.</li> </ul>
Educate patients	<ul> <li>Educate patients on the rare risk of recurrent angioedema with an ARB.</li> <li>Look for signs of lip swelling, difficulty breathing or swallowing, or muffled voice.</li> </ul>
Plan for recurrent angioedema	<ul> <li>Instruct patients to alert provider as soon as possible and seek emergency care.</li> <li>Understand the risk of recurrence is between 2-17%.</li> </ul>

Start an angiotensin system blocker, such as an ARNI (generally preferred), ACEI, or ARB and titrate to target dose in Veterans with HFrEF to reduce mortality and HF-related hospitalizations.

## **Beta blockers (BB)**

Choice of BB is important as benefit is not a class-effect. The preferred beta blockers for the treatment of HF are:<sup>17</sup>

- Bisoprolol
- Metoprolol succinate
- Carvedilol


Initiation or titration of beta blockers may exacerbate fluid retention.

Start low, go slow, and be very cautious in hypervolemic patients. Diuretics may need to be increased temporarily.

### Beta blockers in pulmonary disease


- If a BB is to be used in a patient with reversible airway disease, a cardioselective (B<sup>1</sup>) agent like metoprolol succinate or bisoprolol may be preferred, taking into consideration the risk vs. benefit.<sup>28,29</sup>
- There is a lack of conclusive data demonstrating any clinical harm associated with the use of BB in patients with COPD.<sup>30,31</sup>


### Figure 8. B<sub>1</sub> selectivity of BB used in HFrEF<sup>32</sup>



\*Based on theoretical comparisons using relative receptor activity

Initiate beta blockers and titrate to target doses or maximally tolerated dose in Veterans with HFrEF.





Increasing twice daily carvedilol dose

In the MOCHA Trial, patients with HFrEF receiving 25 mg BID of carvedilol had a significantly decreased mortality rate compared to lower dosages at six months.

### Sodium-glucose co-transporter 2 (SGLT-2) inhibitors

SGLT-2 inhibitors (i.e., empagliflozin and dapagliflozin) have been shown to reduce the composite outcomes of CV death or worsening heart failure over placebo regardless of whether a patient has diabetes or not.<sup>33,34</sup>




Figure 9. SGLT-2 inhibitors decreased CV mortality or slowed HF from worsening<sup>33,34</sup>

Primary composite outcome: worsening HF or death from CVD causes.

The DAPA-HF and EMPEROR-Reduced trials evaluated dapagliflozin and empagliflozin, respectively, in patients with HFrEF in NYHA class II-IV patients on background ARNI/ACEI/ARB therapy. In the DAPA-HF trial there were ~11% of patients on ARNI, while in EMPEROR-Reduced there were ~18%. In both trials there was ~71% mineralocorticoid receptor antagonist use.

### Special considerations when starting SGLT-2 inhibitors for patients with HF:<sup>35-37</sup>

SGLT-2 inhibitor clinical pearls for fluid balance and renal function	
Renal	Loop diuretics
<ul> <li>Ensure adequate kidney function prior to use:</li> <li>Dapagliflozin eGFR ≥ 25 mL/min/1.73 m<sup>2</sup></li> <li>Empagliflozin eGFR ≥ 20 mL/min/1.73 m<sup>2</sup></li> <li>Initial decline in eGFR expected.</li> <li>20-30% decline, consider adjustment of other medications (e.g., ACEI, diuretics) and assess for other causes.</li> <li>&gt; 30% decline, discontinue and evaluate</li> <li>Patients with chronic kidney disease may experience improved renal outcomes.</li> </ul>	If patient is not hypervolemic consider dose reduction of loop diuretic, if concerned about hypovolemia. Educate on managing fluid, how and when to restart diuretic, and when to call the clinic.
Other considerations for SGLT-2 inhibitor use (e.g., blood pressure genital infections) are detailed in the OBG	

Other considerations for SGLT-2 inhibitor use (e.g., blood pressure, genital infections) are detailed in the QRG.


Initiate an SGLT-2 inhibitor in Veterans with HFrEF.

## Mineralocorticoid receptor antagonists (MRA)

MRAs (e.g., spironolactone or eplerenone), previously called aldosterone antagonists (AA), should be considered in HFrEF when the Veteran has an EF  $\leq$  40%, NYHA class II-IV, K+  $\leq$  5mEq/L, and eGFR  $\geq$  30 mL/min/1.73m<sup>2</sup>.

A basic metabolic panel (BMP) is recommended within one week of initiating or titrating MRA to monitor for the presence of hyperkalemia.<sup>16</sup>






death in patients with HFrEF in New York Heart Association (NYHA) class III and IV at the time of enrollment. This study was conducted before beta blockers were widely used for HF; only ~10% of patients were on beta blockers.

### Gynecomastia<sup>38,39</sup>

The incidence of gynecomastia is higher with spironolactone than eplerenone. If a patient experiences gynecomastia on spironolactone, eplerenone should be considered as an alternative.


Add a mineral corticoid receptor antagonist in patients with HFrEF to reduce mortality.

.....



The EMPHASIS-HF trials evaluated CV-related death in patients with HFrEF in NYHA class II. In this study, 87% of patients were on beta blockers. This trial expanded utilization of mineralocorticoid receptor antagonists to include HF NYHA class II—IV.






## Hydralazine and isosorbide dinitrate

- In Black patients with NYHA class III-IV, the addition of hydralazine and isosorbide dinitrate to standard therapy is recommended to improve survival and decreases hospitalization.<sup>16,40</sup>
- Hydralazine and isosorbide dinitrate may play a role in patients who do not tolerate either an ACEI or an ARB due to renal dysfunction, hyperkalemia, or angioedema.<sup>17</sup>

Side effects, drug interactions, and unappealing dosing schedule may impede the utilization of these medications. Starting at a lower dose and utilizing a slower titration to enhance the tolerability of these medications is recommended.<sup>17</sup>

# Figure 12. Hydralazine and isosorbide dinitrate reduced hospitalizations and improved all-cause mortality in Black patients with heart failure<sup>40</sup>



Black patients with NYHA class III or IV HF on standard therapy for heart failure; Study terminated early, secondary to the higher mortality rate in the placebo group. HYD = hydralazine; ISDN = isosorbide dinitrate

Consider adding hydralazine and isosorbide dinitrate in Black patients with HFrEF who remain symptomatic despite concomitant use of ARNI/ACEI/ARB, beta blocker, SGTL-2 inhibitor, and MRA.

# Other medications used in selected patients with HFrEF

### Table 4. Medications with a supplemental role in managing HFrEF<sup>2,17,41-44</sup>

Medication	When to consider	Important notes
lvabradine	<ul> <li>Consider addition in patients with :</li> <li>NYHA Class II-III HF, AND</li> <li>EF ≤ 35%, AND</li> <li>in normal sinus rhythm with a resting HR</li> <li>&gt; 70 BPM despite optimal use of GDMT, or</li> <li>if the patient is unable to tolerate BB or has contraindications to BB<sup>17</sup></li> </ul>	Initiate and titrate BB to maximally tolerated dose BEFORE assessing resting HR for ivabradine consideration.
Vericiguat	<ul> <li>Consider addition in patients with:</li> <li>recent HF hospitalization or outpatient IV diuretic use</li> <li>no current use of long-acting nitrates (e.g., isosorbide dinitrate)</li> <li>other mortality-reducing HF medications optimized</li> </ul>	Vericiguat reduced composite CV death and HF hospitalization by 10%, but the benefit is largely driven by a reduction in HF hospitalizations.
Digoxin	Consider use in HFrEF patients with: • persistent symptoms despite GDMT	Target concentration < 1ng/ml (ideally 0.5 to 0.9 ng/ml). Patients with elevated trough levels, especially > 2 ng/mL, and those with hypokalemia, hypomagnesemia, hypercalcemia, and hypothyroidism are at increased risk of digoxin toxicity. See the QRG for other risk factors.
Omega-3 polyunsat- urated fatty acids (PUFA)	Consider use in patients with NYHA class II-IV symptoms despite GDMT.	Benefit was seen after three years in patients with EF < 40%. HF dose is 1,000 mg EPA/DHA daily, much lower than for lowering triglycerides. EPA/DHA are a portion of fatty acids in fish oil and product contents vary widely. Can increase LDL and the risk of bleeding
Intravenous iron therapy	<ul> <li>Consider use in HFrEF patients with:</li> <li>NYHA stage II and III, despite maximally tolerated GDMT for a least 4 weeks prior to infusion</li> <li>EF &lt; 45% or EF &lt; 50% if recently hospitalized for HF</li> <li>Ferritin &lt;100 mg/dL or 100-299 mg/dL if transferrin saturation is &lt; 20%</li> </ul>	Treating iron deficiency with intravenous iron infusions may alleviate HF symptoms, improve exercise capacity, and quality of life and reduces HF re-hospitalizations in symptomatic patients with EF < 50%. <sup>15,43,44</sup> Oral iron is not effective. Work with hematology to develop a treatment plan.

## Medications for heart failure with preserved EF

The medications used for managing patients with HFrEF have not all been found to provide the same benefit for patients with HFpEF (EF  $\geq$  50%). Most studies did not find a benefit in co-primary outcomes of CV death or HF hospitalization. Some studies suggest a decrease in HF hospitalization.


Table 5. Sum	mary of studie	es in patients	with HFpEF <sup>2,15,47-51</sup>
--------------	----------------	----------------	----------------------------------

Medication	Mortality decrease	HF hospitalization decrease
SGLT-2 inhibitor	?*	$\checkmark$
ARNI (vs. ARB)	X	✓ (sub-group analysis)**
MRA	X	✓ (sub-group analysis) <sup>#</sup>
ARB	X	Possible benefit - conflicting data

**X** = no benefit;  $\checkmark$  = benefit; For characteristics of patients most likely to benefit, see QRG.

\*The primary outcome in the EMPEROR-preserved and DELIVER trials consisted of composites of CV death or heart failure hospitalization (HFH) or CV death or worsening heart failure (HFH or urgent visit for HF) respectively and did show a significant improvement. However, this effect was mainly related to a lower risk of HFH and the impact on mortality is not clear. \*\*The PARAGON-HF did not show a difference in the primary composite endpoint of cardiovascular death or total HF hospitalization. However, in prespecified subgroup analyses a benefit was seen in those with an LVEF below 57% and in women. # The TOPCAT trial did not show a difference in the primary composite outcome of CV death, aborted cardiac arrest, or HFH. However, when looked at as a component of the primary outcome there was a significant decrease in HFH.





The EMPEROR-Preserved and DELIVER trials enrolled 5,899 and 6,263 patients with NYHA class II-IV with LFEF > 40% to 10 mg of empagliflozin or 10 mg of dapagliflozin respectively. The benefit in each trial was driven by a reduction in HF hospitalization (HR 0.79; 95% CI: 0.60-0.83 and HR 0.77; 95% 0.67–0.89 respectively).

# Assessing heart failure symptoms and fluid management

=

Fluid retention (hypervolemia) in patients with HF can be the stimulus for acute decompensated HF that requires hospitalization.<sup>52</sup>

It is important that patients with HF are educated on:

- Weighing themselves daily and maintaining their dry weight
- Taking their medications as prescribed
- Monitoring how they feel
- Understanding the symptoms of HF and the best responses to stay in balance

### Table 6. Sample HF assessment questions<sup>53</sup>


Breathing	Swelling	Neurologic changes
<ul> <li>What types of activities make you short of breath (SOB) or more SOB?</li> <li>Are you experiencing SOB while sitting still?</li> </ul>	<ul> <li>Are you having any swelling in your feet, ankles, legs, or stomach?</li> <li>Is this new or worse than before?</li> </ul>	<ul> <li>Are you having any dizziness? New or worse than before?</li> <li>Are you having any confusion? New or worse than before?</li> </ul>
<ul> <li>Are you able to sleep lying down? With how many pillows, or do you need to sleep in a chair?</li> </ul>	<ul> <li>Have you gained unusual or unexplained weight?</li> <li>Have you gained more than three pounds in one day or five pounds in one week?</li> </ul>	

Assess patients for symptoms of HF at each visit including physically assessing for edema. Remind patients of the importance of daily monitoring and acting on worsening symptoms.

### Diuretics

Diuretics are often needed to help many patients with symptomatic HF remain euvolemic. In patients with HFrEF they should be combined with ARNI/ACE/ARB, BB, MRA, and SGLT-2 inhibitors in most patients with evidence of, or a prior history of, fluid retention.<sup>2</sup> In addition, moderate dietary sodium restriction can be used in conjunction with oral diuretics.<sup>40</sup>

### Figure 14. Starting a diuretic<sup>2,54</sup>



\*Avoid if hypersensitivity to furosemide, bumetanide, or torsemide. Use ethacrynic acid in these patients.


### Risks of diuretics:2,54

- Hypokalemia, hypomagnesemia, hyponatremia, electrocardiogram (ECG) changes, hypotension, acute kidney injury
- Combining diuretics increases risk of adverse events.

Add diuretics to guidelinedirected medical therapy for relief of symptoms due to volume overload in patients with HF.

.....

# Unexpected rapid weight gain of three pounds over one day or five pounds in a week



- 1. Check adherence to medications, diet, and fluid restrictions.\*
- 2. Review biochemistry and previous diuretic response.
- 3. Adjust loop diuretic dose (increase if fluid overloaded or decrease if dehydrated).
  - a. Volume overload:
    - i. An effective dose of a diuretic will elicit a urinary response within 30 to 60 minutes and results in increased urinary frequency for at least two hours.
    - ii. If urinary response is not noted within 60 minutes, consider increasing the dose by 50% to 100% to elicit diuresis.
    - iii. If urinary response is noted but the patient remains fluid overloaded and is not losing one to two pounds/day or showing improvement in fluid retention/congestion, consider increasing dosing frequency or switching diuretic or adding thiazide diuretic.
  - b. Volume contraction:
    - i. Trial diuretic reduction until minimal dose is achieved to maintain baseline weight.
- 4. Monitor renal function, potassium, magnesium, and response to therapy.

\*Although fluid restriction is a common recommendation, it has no effect on clinical outcomes and has minimal evidence to support the practice.<sup>16</sup>

# Treatment of heart failure in patients with chronic kidney disease (CKD)

Heart failure treatment recommendations for patients with concomitant renal dysfunction in general are not different from those for patients with preserved renal function.<sup>56-58</sup> There is often concern that medications like ACEI, ARB, and ARNI will lead to deterioration of renal function and subsequently lead to worsening of HF. Despite the increase in serum creatinine with these medications, usually < 20% in the first month of treatment, there is often improvement seen in hospitalization and survival.<sup>57</sup>

SGLT-2 inhibitors slow progression of kidney disease in addition to benefits to managing heart failure. While useful for renal protection, initiation in low eGFR or hypovolemia are not recommended.<sup>60</sup>

Patients with CKD are more likely to develop hyperkalemia. Closer monitoring of renal function and electrolytes (potassium) is important to assist in guiding treatment decisions.<sup>57</sup> Treatment with SGTL-2 inhibitors may help lower serum potassium.<sup>61</sup>

# ACEI and ARB can be continued when:<sup>56,59</sup>

- eGFR decline at two months is less than 30%
- Serum Potassium is ≤ 5.5



### Figure 16. Measures to prevent and manage hyperkalemia<sup>61-64</sup>

Initiate low potassium diet	<ul> <li>Initiate low potassium diet in patients at high risk for hyperkalemia.</li> <li>Limit potassium intake to 2 to 3 gm per day (e.g., one cup banana, sliced = 537 mg).</li> <li>Avoid potassium-based salt substitutes.</li> </ul>
HANDON HA	
Conduct medication review	<ul> <li>Avoid or discontinue potassium-increasing drugs.</li> <li>Start SGLT-2 inhibitor, if not already taking.</li> <li>Initiate or titrate loop (preferred) or thiazide diuretic, if appropriate.</li> <li>Reduce the dose or discontinue RAAS* medication if unable to control potassium with diet.</li> </ul>
Consider referral to specialist	<ul> <li>Potential for concomitant therapy with potassium binders</li> <li>Recurrent potassium ≥5.5 mEq/L despite trial of above measures</li> <li>Evaluate risk versus benefit of continued RAAS.</li> </ul>

\*RAAS = renin-angiotensin-aldosterone system medications (e.g., ARNI, ACEI, ARB, MRA)

## Medications to avoid or use with caution in heart failure


### Table 7. Medications to avoid or use cautiously in HF<sup>16,65-70</sup>

Medication	lssue
	DISCONTINUE
Systemic nonsteroidal anti-inflammatory drugs (NSAIDs) (both COX-selective and non- selective inhibitors)	<ul> <li>May cause sodium and water retention, peripheral vasoconstriction, worsen heart failure, and decrease renal function</li> <li>Acute renal failure may be more likely when these agents are used in combination with an ACEI, ARB, ARNI, or diuretic</li> </ul>
Intermittent claudication agents (e.g., cilostazol)	Several drugs with the same pharmacologic effect as cilostazol have caused decreased survival compared to placebo in patients with NYHA class III-IV heart failure. Effects may be seen within one month of starting cilostazol. <b>Cilostazol is contraindicated in patients with</b> <b>heart failure of any severity.</b>
Nifedipine	<ul> <li>Negative inotropic effects</li> <li>Increased risk of hospitalization for HF exacerbation in patients with HFrEF</li> <li>Use amlodipine or felodipine if a dihydropyridine calcium channel blocker is needed in a patient with HFrEF</li> </ul>
Non-dihydropyridine calcium channel blockers (e.g., verapamil and diltiazem)	<ul> <li>Negative inotropic effects</li> <li>May be useful in HFpEF when slowing HR could increase filling time</li> <li>Contraindicated in HFrEF</li> </ul>
Thiazolidinediones (e.g., rosiglitazone, pioglitazone)	<ul> <li>May cause or exacerbate heart failure through increased fluid retention and blood pressure</li> <li>Consider conversion to an anti-diabetic drug with HF benefits such as an SGLT-2 inhibitor</li> </ul>
Some antiarrhythmics (e.g., flecainide, propafenone, dronedarone)	<ul> <li>Increased risk of hospitalization for HF exacerbation</li> <li>Increased risk of mortality</li> <li>Preference is for heart failure-specific beta blocker, amiodarone, or dofetilide</li> </ul>
Dipeptidyl peptidase-4 (DPP4) inhibitors	<ul> <li>Increased risk of developing HF in patient with pre-existing heart and/or kidney disease; Avoid saxagliptin and alogliptin, use sitagliptin if alternative therapies (i.e., SGLT-2 inhibitors, GLP-1 receptor agonists) with cardiovascular benefit are not an option.</li> </ul>

Medication	Issue
Corticosteroids	<ul> <li>Increased fluid and sodium retention and blood pressure</li> </ul>
Anticoagulant	<ul> <li>Warfarin or direct oral anticoagulants do not improve thrombotic outcomes but increase bleeding risk in patients with chronic HF without an indication (e.g., atrial fibrillation, venous thromboembolism, prior thrombotic event, or cardioembolic source).</li> </ul>
Miscellaneous	<ul> <li>Clozapine may cause cardiomyopathy and myocarditis.</li> <li>Tricyclic antidepressants or cyclobenzaprine may prolong QT interval and contribute to hypotension.</li> <li>Avoid or use caution with medications that increase fluid retention (e.g., gabapentin) and contribute to peripheral edema.</li> <li>Doxazosin may worsen underlying myocardial dysfunction.</li> <li>Tumor necrosis factor (TNF) inhibitors (e.g., infliximab, adalimumab, etanercept) may exacerbate HF.</li> </ul>

## Medication treatment algorithm for heart failure

### Figure 17. Guideline-directed medical therapy across heart failure stages<sup>16</sup>



See the ACC/AHA/SFSA Guideline for Management of Heart Failure for specific patient population criteria.<sup>16</sup>

# **Care coordination**

### Remote patient monitoring-home telehealth (RPM-HT)<sup>71</sup>

- RPM-HT clinics may reduce all-cause mortality and the incidence of hospitalizations related to HF compared to patients receiving usual care alone.
- Enroll patients with HFrEF in RPM-HT to reduce mortality and HF hospitalizations.<sup>71</sup>



### Referrals

- Appropriate and timely referral to an HF specialist is essential in selected patients to optimize therapies (e.g., device therapy) and evaluate advanced HF care options.
- Depression and anxiety are frequently associated with cardiovascular disease and increase mortality.<sup>72</sup> Screen patients frequently for these disorders and consider treatment and/or referral to mental health if appropriate.

Presence of any of these high-risk features would support clinical consideration for referral to an advanced heart failure specialist.

### A team-based approach

- Every patient with a diagnosis of HF should be assigned to a PACT Team.
- A principal HF manager should be identified for all patients (cardiology or PCP).
- If managed by primary care, ongoing reassessment of needs recommended.

Use "INEED HELP" to identify candidates for referral to a HF specialist<sup>17</sup>

- I: IV inotropes
- N: NYHA Class IIIB/IV HF or persistently elevated natriuretic peptides
- **E**: End-organ dysfunction
- **E**: Ejection fraction < 35%
- **D**: Defibrillator shocks


- **H**: Hospitalizations > 1
- **E**: Edema, despite escalating diuretics
- L: Low blood pressure, high heart rate
- P: Prognostic medication: progressive intolerance or down-titration of guideline-directed medical therapy

### Timely post-hospitalization follow-up

- Timely follow-up after discharge from a HF hospitalization can reduce the risk of readmission.<sup>73</sup> Visits should occur within 7 days of discharge.<sup>16,19</sup>
- At post-discharge visits, providers should evaluate and address precipitants of HF exacerbation, barriers to care (including self-care), volume status as well as renal function and electrolytes, medication regimen and adherence, patient education, and opportunities to initiate and/or titrate GDMT.<sup>16</sup>

Engage patients in appropriate care coordination, including RPM-HT, referring to cardiology specialists, and post-hospitalization follow-up.

## **Summary**



### **Contributing authors:**

Garrett Aikens, PharmD, BCACP Heidi Cantrell, PharmD, BCPS Ellen Dancel, PharmD, MPH Stacy M. Hargrove, PharmD, BCPS, BCGP Tomasz Jurga, PharmD, BCPS, BCACP, BCCP, CDCES Calleen Lavinghousez, PharmD, BCPS, BCPP David Parra, PharmD, FCCP, FAHA Addison Ragan, PharmD, BCPS Bridget Roop, PharmD Heather Tanner, PharmD Anishka Walker, PharmD

### We thank our expert reviewers:

Shawn D. Anderson, PharmD, BCACP Jennifer Clemente, PharmD Elaine Furmaga, PharmD Julie Gee, RN, MSN, CNP, CHFN Amber Gossett, PharmD, BCPS Mike McFarland, PharmD Steve Orlando, PharmD, BCACP Danial Schwartz, MD

# National academic detailing service consultants:

Sarah J. Popish, PharmD, BCPP Chad Kay, PharmD, BCPS

#### REFERENCES

1. Tsao CW, Aday AW, Almarzoog ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022:Cir0000000000001052. 2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327. 3. Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254-e743. 4. Grubb AF, Greene SJ, Fudim M, Dewald T, Mentz RJ. Drugs of Abuse and Heart Failure. J Card Fail. 2021;27(11):1260-1275. 5. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27(5):1214-1218. 6. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387(10017):435-443. 7. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769-1781. 8. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013(1):CD004816. 9. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. 10. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357.

11. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. 12. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. *Circulation*. 2001; 103(22):2668-2673. 13. Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62(15):1365-1372. 14. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. Jama. 2013;310(1):66-74. 15. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017; 23(8):628-651. 16. Heidenreich PA, Bozkurt B, Aquilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022:101161cir0000000000001063. 17. Maddox TM, Januzzi JL, Jr., Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772-810. 18. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. 19. A team based approach to the management of patients with heart failure within the Department of Veterans Affairs. October 2021. 20. National Coverage Determination (NCD). Cardiac rehabilitation programs for chronic heart failure. Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare-coverage-database/view/ ncd.aspx?ncdid=359&ncdver=1. Published 2014. Accessed February 10, 2022. 21. McMurray JJ. Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. 22. Mann DL, Givertz MM, Vader JM, et al. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022;7(1):17-25. 23. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-776. 24. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312-2318. 25. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. 26. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840-1848. 27. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94(11):2807-2816. 28. Gurwitz JH, Magid DJ, Smith DH, et al. Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease. J Am Geriatr Soc. 2017;65(12):2610-2618. 29. Liao KM, Lin TY, Huang YB, Kuo CC, Chen CY. The evaluation of  $\beta$ -adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. Int J Chron Obstruct Pulmon Dis. 2017;12:2573-2581. 30. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780-1787.

**31.** Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2004;44(3):497-502. 32. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000 Feb 8;101(5):558-69. 33. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. 34. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. 35. Pamulapati LG, Rochester-Eyequokan CD, Pincus KJ. Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process. Am J Health Syst Pharm. 2020;77(21):1727-1738. **36.** Solomon SD, de Boer RA, DeMets D, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23(7):1217-1225. 37. Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction. AstraZeneca. Accessed May 25, 2022. https://www.astrazeneca-us.com/content/az-us/media/ press-releases/2022/farxiga-met-primary-endpoint-in-deliver-phase-III-trial.html. **38.** Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78(8):902-907. 39. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. 40. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-2057. 41. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-533. 42. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-885. **43.** Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-1893. 44. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223-1230. 45. Anker SD, Comin Colet J, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361(25):2436-2448. 46. Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-1904. 47. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392. 48. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-1620. 49. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-781. 50. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16): 1451-1461. **51.** Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Aug 27. Epub ahead of print. 52. Albert NM. Fluid management strategies in heart failure. Crit Care Nurse. 2012;32(2):20-32; quiz 34. 53. Self-Check Plan for HF Management. American Heart Association (2015) https://www.heart.org/-/ media/files/health-topics/heart-failure/hf-symptom-tracker.pdf. 54. Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother. 2009;43(11):1836-1847. 55. National Heart Foundation of Australia. Fluid management algorithm in heart failure. https://www.heartonline.org.au/media/DRL/Fluid\_management\_algorithm\_in\_ heart failure.pdf. Published 2014. Accessed January 31, 2022. 56. Bakris GL, Weir MR. Angiotensinconverting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685-693. 57. Damman K, Tang WH, Felker GM, et al. Current evidence

on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. J Am Coll Cardiol. 2014;63(9):853-871. 58. Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. *Biomed Res* Int. 2014;2014:937398. 59. Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy. 2004;24(5):697-702; discussion 702-693. 60. Bailey CJ, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr Diab Rep. 2022;22(1):39-52. 61. Ferreira JP, Butler J, Zannad F, et al. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2022;79(12):1129-1137. 62. DeFilippis EM, Desai AS. Treatment of Hyperkalemia in Heart Failure. Curr Heart Fail Rep. 2017;14(4):266-274. 63. Sarwar CM, Papadimitriou L, Pitt B, et al. Hyperkalemia in Heart Failure. J Am Coll Cardiol. 2016;68(14):1575-1589. 64. VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives. Patiromer (VELTASSA TM). Criteria for Use. February 2017. 65. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust. 2011;194(8):405-409. 66. Maxwell CB, Jenkins AT. Drug-induced heart failure. Am J Health Syst Pharm. 2011;68(19):1791-1804. 67. Murphy N, Mockler M, Ryder M, Ledwidge M, McDonald K. Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail. 2007;13(3):227-229. 68. National Heart Foundation of Australia. Potentially harmful drugs to avoid in heart failure. https://www.heartonline.org.au/media/DRL/Potentially\_harmful\_drugs\_to\_ avoid in heart failure.pdf. Published 2016. Accessed January 31, 2022. 69. Page RL, 2nd, O'Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(6):e32-69. 70. Spieker LE, Ruschitzka FT, Lüscher TF, Noll G. The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail. 2002;4(4):403-410. 71. Kotb A, Cameron C, Hsieh S, Wells G. Comparative effectiveness of different forms of telemedicine for individuals with heart failure (HF): a systematic review and network meta-analysis. PLoS One. 2015;10(2):e0118681. 72. Watkins LL, Koch GG, Sherwood A, et al. Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease. J Am Heart Assoc. 2013;2(2):e000068. 73. Howie-Esquivel J, Carroll M, Brinker E, et al. A Strategy to Reduce Heart Failure Readmissions and Inpatient Costs. Cardiol Res. 2015;6(1):201-208.



U.S. Department of Veterans Affairs

Veterans Health Administration PBM Academic Detailing Services

This reference guide was created to be used as a tool for VA providers and is available from the Academic Detailing SharePoint.

These are general recommendations only; specific clinical decisions should be made by the treating provider based on an individual patient's clinical condition.

VA PBM Academic Detailing Services Email Group:

PharmacyAcademicDetailingProgram@va.gov

VA PBM Academic Detailing Services SharePoint Site: https://dvagov.sharepoint.com/sites/vhaacademicdetailing

VA PBM Academic Detailing Services Public Website: http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp